PSB 0777 ammonium hydrate is a potent and selective adenosine A2A receptor full agonist, exhibiting K i values of 44.4 nM for rat A2A receptors and 360 nM for human A2A receptors. For rat and human A1 receptors, it shows significantly lower affinity with K i values of ≥10000 nM and 541 nM, respectively. The compound demonstrates poor brain penetration and is not orally absorbable. It is of interest in research related to inflammatory bowel disease (IBD) [1] [2] [3].

PSB 0777 ammonium hydrate (compound 7) exhibits high specificity for A2A adenosine receptors (A2A AR), demonstrating a greater than 225-fold selectivity compared to other AR subtypes, with K i values above 10000 nM for A2B AR and even higher for A3 AR. As a full agonist at A2A AR, it has an effective concentration (EC50) of 117 nM in CHO-K1 cells [1]. It also interacts with human β1 and β3 adrenergic receptors, showing K i values of 4.4 μM and 3.3 μM, respectively [2]. Additionally, in ex vivo experiments, PSB 0777 ammonium hydrate enhances acetylcholine-induced contractions in both untreated and inflamed rat ileum/jejunum preparations in a concentration-dependent manner at 0.1 µM, 1 µM, and 10 µM [1].

PSB 0777 ammonium hydrate administered at 0.4 mg/kg/day orally from day 5 to 10 significantly decreases inflammatory cell infiltration and improves colonic mucosal structure [3]. Dose-dependent hypothermia and reduced activity levels in C57BL/6J mice are observed with intraperitoneal injections of 0.03, 0.3, and 3 mg/kg of the compound [2]. Following oral administration, PSB 0777 ammonium hydrate is not systemically absorbed by the digestive mucosa. Plasma concentrations in rats peak at sub-5 nM levels 30 minutes after oral dosing with 0.4 mg/kg/day and are undetectable at 60 minutes. Conversely, intraperitoneal injection at the same dosage yields significant plasma concentration at 30 minutes, which diminishes by the 60-minute mark and is non-detectable at both 120 and 240 minutes [3].